237,620 Shares in Inozyme Pharma, Inc. (NASDAQ:INZY) Acquired by Walleye Capital LLC

Walleye Capital LLC purchased a new stake in Inozyme Pharma, Inc. (NASDAQ:INZY) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 237,620 shares of the company’s stock, valued at approximately $658,000. Walleye Capital LLC owned about 0.37% of Inozyme Pharma as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in INZY. State Street Corp raised its position in shares of Inozyme Pharma by 5.0% in the 3rd quarter. State Street Corp now owns 1,050,420 shares of the company’s stock worth $5,494,000 after buying an additional 50,386 shares during the period. Jane Street Group LLC increased its stake in Inozyme Pharma by 7.5% during the third quarter. Jane Street Group LLC now owns 49,460 shares of the company’s stock worth $259,000 after acquiring an additional 3,443 shares during the last quarter. Barclays PLC raised its holdings in shares of Inozyme Pharma by 261.4% in the 3rd quarter. Barclays PLC now owns 76,730 shares of the company’s stock worth $401,000 after purchasing an additional 55,497 shares during the period. Geode Capital Management LLC lifted its stake in shares of Inozyme Pharma by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock valued at $6,126,000 after purchasing an additional 19,499 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Inozyme Pharma during the 3rd quarter worth about $64,000. 88.30% of the stock is owned by hedge funds and other institutional investors.

Inozyme Pharma Stock Up 5.2 %

Shares of Inozyme Pharma stock opened at $1.03 on Wednesday. Inozyme Pharma, Inc. has a 1-year low of $0.72 and a 1-year high of $6.24. The company has a market capitalization of $66.17 million, a PE ratio of -0.66 and a beta of 1.39. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. The business has a 50-day moving average of $1.04 and a 200-day moving average of $2.34.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on INZY shares. Wells Fargo & Company reduced their price target on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. Raymond James reduced their target price on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a report on Wednesday, March 12th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Inozyme Pharma in a report on Tuesday, April 8th. Piper Sandler cut their price objective on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 11th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $7.00 target price (down previously from $12.00) on shares of Inozyme Pharma in a research report on Monday, March 10th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inozyme Pharma has a consensus rating of “Buy” and an average target price of $14.63.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.